Muscle involvement in rheumatoid arthritis: Clinicopathological study of 21 symptomatic cases

被引:53
作者
Miro, O
Pedrol, E
Casademont, J
GarciaCarrasco, M
Sanmarti, R
Cebrian, M
Grau, JM
机构
[1] UNIV BARCELONA,HOSP CLIN BARCELONA,DEPT INTERNAL MED,MUSCLE RES UNIT,E-08036 BARCELONA,SPAIN
[2] UNIV BARCELONA,HOSP CLIN BARCELONA,RHEUMATOL UNIT,E-08036 BARCELONA,SPAIN
关键词
RA; myopathy; toxic; inflammatory;
D O I
10.1016/S0049-0172(96)80007-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the current study was to analyze the frequency and characteristics of symptomatic myopathies occurring in rheumatoid arthritis (RA) patients, to correlate these findings with clinical data, and to evaluate their therapeutic implications. All RA patients from a cohort of 350 RA patients from a single institution who developed muscular symptomatology during an 8-year period were included in the study (n = 21). Clinical and laboratory data and electromyographic results were recorded in all cases, and an open muscle biopsy was performed. Weakness and muscle atrophy were the most common symptoms. Serum creatine kinase was increased in 8 cases (38%). Histopathologic study showed type 2 atrophy in 12 cases. In 13 cases, a treatable disease was diagnosed: dermatomyositis (n = 2), d-penicillamine-related dermatomyositis (n = 2), polymyositis (n = 1), muscular mononuclear cell infiltration (n = 3), polyarteritis nodosa (n = 1), glucocorticoid myopathy (n = 3), and toxic chloroquine myopathy (n = 1). In all but 1 patient, muscular clinical response to new therapy and/or drug withdrawal was satisfactory. Although symptomatic muscular involvement in RA is low (6% in the current series), we have found that nearly two thirds of cases were caused by potentially treatable conditions, mainly myositis or toxic myopathies. Copyright (C) 1996 by W.B. Saunders Company
引用
收藏
页码:421 / 428
页数:8
相关论文
共 41 条
[1]  
ABEL T, 1980, ANN INTERN MED, V93, P477
[2]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]   STEROID MYOPATHY IN CONNECTIVE-TISSUE DISEASE [J].
ASKARI, A ;
VIGNOS, PJ ;
MOSKOWITZ, RW .
AMERICAN JOURNAL OF MEDICINE, 1976, 61 (04) :485-492
[4]  
AVINAZUBIETA JA, 1995, BRIT J RHEUMATOL, V34, P166
[5]   COMPUTER-ASSISTED ANALYSIS OF 153 PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS [J].
BOHAN, A ;
PETER, JB ;
BOWMAN, RL ;
PEARSON, CM .
MEDICINE, 1977, 56 (04) :255-286
[6]  
BROOKE MH, 1972, ARCH PATHOL, V94, P101
[7]  
CARDELLACH F, 1989, LANCET, V2, P44
[8]   CLINICAL CHARACTERISTICS AND PROGNOSIS OF VASCULITIC MONONEUROPATHY MULTIPLEX [J].
CHANG, RW ;
BELL, CL ;
HALLETT, M .
ARCHIVES OF NEUROLOGY, 1984, 41 (06) :618-621
[9]  
CHEVALIER X, 1993, J RHEUMATOL, V20, P1259
[10]   HYDROXYCHLOROQUINE COMPARED WITH PLACEBO IN RHEUMATOID-ARTHRITIS - A RANDOMIZED CONTROLLED TRIAL [J].
CLARK, P ;
CASAS, E ;
TUGWELL, P ;
MEDINA, C ;
GHENO, C ;
TENORIO, G ;
OROZCO, JA .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (11) :1067-1071